8FQV image
Entry Detail
PDB ID:
8FQV
Keywords:
Title:
apo ADC-30 beta-lactamase
Biological Source:
Source Organism:
PDB Version:
Deposition Date:
2023-01-06
Release Date:
2023-07-05
Method Details:
Experimental Method:
Resolution:
1.48 Å
R-Value Free:
0.20
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Beta-lactamase
Chain IDs:A (auth: B), B (auth: A)
Chain Length:361
Number of Molecules:2
Biological Source:Acinetobacter baumannii
Ligand Molecules
Primary Citation
Synthesis of a Novel Boronic Acid Transition State Inhibitor, MB076: A Heterocyclic Triazole Effectively Inhibits Acinetobacter -Derived Cephalosporinase Variants with an Expanded-Substrate Spectrum.
J.Med.Chem. 66 8510 8525 (2023)
PMID: 37358467 DOI: 10.1021/acs.jmedchem.3c00144

Abstact

Class C Acinetobacter-derived cephalosporinases (ADCs) represent an important target for inhibition in the multidrug-resistant pathogen Acinetobacter baumannii. Many ADC variants have emerged, and characterization of their structural and functional differences is essential. Equally as important is the development of compounds that inhibit all prevalent ADCs despite these differences. The boronic acid transition state inhibitor, MB076, a novel heterocyclic triazole with improved plasma stability, was synthesized and inhibits seven different ADC β-lactamase variants with Ki values <1 μM. MB076 acted synergistically in combination with multiple cephalosporins to restore susceptibility. ADC variants containing an alanine duplication in the Ω-loop, specifically ADC-33, exhibited increased activity for larger cephalosporins, such as ceftazidime, cefiderocol, and ceftolozane. X-ray crystal structures of ADC variants in this study provide a structural context for substrate profile differences and show that the inhibitor adopts a similar conformation in all ADC variants, despite small changes near their active sites.

Legend

Protein

Chemical

Disease

Primary Citation of related structures